0001683168-23-000813.txt : 20230213 0001683168-23-000813.hdr.sgml : 20230213 20230213161021 ACCESSION NUMBER: 0001683168-23-000813 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230213 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230213 DATE AS OF CHANGE: 20230213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AETHLON MEDICAL INC CENTRAL INDEX KEY: 0000882291 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133632859 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37487 FILM NUMBER: 23618490 BUSINESS ADDRESS: STREET 1: 11555 SORRENTO VALLEY ROAD, SUITE 203 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-459-7800 MAIL ADDRESS: STREET 1: 11555 SORRENTO VALLEY ROAD, SUITE 203 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: BISHOP EQUITIES INC DATE OF NAME CHANGE: 19930602 8-K 1 aethlon_8k.htm FORM 8-K
0000882291 false 0000882291 2023-02-13 2023-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 13, 2023

 

AETHLON MEDICAL, INC.

(Exact name of Registrant as Specified in Its Charter)

 

Nevada 001-37487 13-3632859

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

11555 Sorrento Valley Road, Suite 203

San Diego, California

 92121
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (619) 941-0360

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 AEMD The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On February 13, 2023, Aethlon Medical, Inc. issued a press release announcing its financial results for the quarter ended December 31, 2022. A copy of this press release is attached hereto as Exhibit 99.1.

 

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
   
99.1   Press Release dated February 13, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 13, 2023

 

Aethlon Medical, Inc.

     
     
  By:   /s/ James B. Frakes
 

Name:

 

  

James B. Frakes

Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 3 

 EX-99.1 2 aethlon_ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

 

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

 

SAN DIEGO, February 13, 2023 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.

 

Company Updates

 

Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood. This action has potential applications in cancer, where cancer associated exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.

 

The Company recently contracted with NAMSA, LLC 2023 (NAMSA), www.namsa.com, a world-leading MedTech CRO offering global end-to-end development services, to direct our planned oncology study in Australia and the United States. This new clinical trial in oncology is planned to be a safety, feasibility and dose finding trial in solid tumors failing anti-PD-1 antibodies. We believe that this trial will help inform the design of future efficacy trials of our Hemopurifier in oncology. The Company plans to initiate this trial first in Australia and then in the United States.

 

We recently hired Lee Arnold, PhD, as our new Chief Scientific Officer. Dr. Arnold is a creative scientific leader with 36 years of accomplishments in molecularly-targeted drug discovery. After an initial eight publications in biophysics and biochemistry as an undergraduate at University of Waterloo, he earned a PhD in Organic Chemistry from University of Alberta. Dr. Arnold began his career in pharma research at Syntex, Inc. (Canada), and then joined Pfizer Inc., where he was the inventor of Tarceva® (erlotinib) for non-small cell lung cancer, or NSCLC. During his tenure at BASF/Abbott Bioresearch Center, he established medicinal & combinatorial chemistry operations, and initiated and led two multinational multidisciplinary projects in angiogenesis, ultimately leading to linifanib (ABT-869). As Vice President of Research at OSI Pharmaceuticals, Dr. Arnold and his teams discovered four oncology development candidates, including the “first-in-class” agents linsitinib (IGF-1R), and ASP7486 (TORC1/2).

 

Dr. Arnold also has served as Chief Scientific Officer (CSO) in a number of innovative start-up biotechnology companies. Just prior to joining Aethlon Medical, Dr. Arnold was the CSO and cofounder of Pardes Biosciences, Inc., which was established at the start of the COVID pandemic as a virtual company that discovered and advanced the oral protease inhibitor, pomotrelvir, into clinical trials for SARS-CoV2 in only 17 months. Dr. Arnold’s inventive and leadership contributions in drug discovery and development to date have resulted in an approved drug, and 16 additional development candidates, currently fueling eight clinical trials in oncology, immunology and virology. These achievements are documented in over 94 published patents and applications, and more than 39 peer-reviewed publications.

 

Charles J. Fisher, Jr., MD, our Chief Executive Officer, stated “we are delighted to have Lee Arnold join our team. He has an extensive career in science and he has led the product development at five previous companies. We look forward to his active leadership of our research team.”

 

Our ongoing COVID-19 trial in India for patients in the ICU at Medanta Medicity Hospital continues to be open for enrollment with one patient treated to date.

 

 

 

 1 
 

 

We also have ongoing preclinical studies to expand the potential utility of the Hemopurifier. These studies include the Monkeypox (mPox) experiment underway at Battelle Labs to examine the in vitro removal of the currently circulating strain of mPox by a miniature version of our Hemopurifier.

 

We also recently entered into a materials transfer agreement with the UCSF Medical Center for the study of Post-acute Sequelae of COVID-19 infection (PASC), also known as “Long COVID-19.” In this study, we will receive plasma samples from patients with PASC, as well as from patients with prior COVID-19 without PASC symptoms. The objective of this study is to perform in vitro analysis of exosomes to determine the viability of PASC as a therapeutic target for the Hemopurifier.

 

Financial Results for the Third Quarter Ended December 31, 2022

 

As of December 31, 2022, Aethlon Medical had a cash balance of approximately $17.5 million.

 

Consolidated operating expenses for the three months ended December 31, 2022 were approximately $2.85 million, compared to $2.545 million for the three months ended December 31, 2021. This increase of approximately $305,000, or 12%, in the 2022 period was due to increases in professional fees of $296,000 and in payroll and related expenses of $49,000, offset by a decrease in general and administrative expenses of $40,000.

 

The $296,000 increase in professional fees in the 2022 period was primarily due to the combination of a $145,000 increase in contract labor expense associated with product development and scientific analytical services, a $73,000 increase in scientific consulting expense, a $71,000 increase in legal fees, and a $22,000 increase associated with recruiting. These expenses were partially offset by a $14,000 decrease in accounting expenses.

 

The $49,000 increase in our payroll and related expenses in the 2022 period was due to an increase of $167,000 in salary expense and an increase of $62,000 of stock-based compensation expense related to increased headcount, offset by a decrease of $180,000 in relocation expense.

 

The $40,000 decrease in administrative expenses in the 2022 period was primarily due to a $75,000 decrease in clinical trial expenses, a $19,000 decrease in rent expense and a $20,000 decrease in licenses and permits, which was partially offset by a $60,000 increase in depreciation expense.

 

Aethlon did not record government contract revenue in the three months ended December 31, 2022. We recorded $17,117 in government contract revenue in the three months ended December 31, 2021. As of December 31, 2022, the Company had approximately $574,000 of deferred revenue related to those government contracts as a result of not achieving certain milestones in the contracts. The NIH award contract ended on September 15, 2022 and we presented the required final report to the NCI. Once the NCI completes the close out review of the contract, we expect to recognize as revenue the $574,000 currently recorded as deferred revenue on our December 31, 2022 balance sheet.

 

As a result of the changes in revenues and expenses noted above, our net loss increased to approximately $2,850,000 in the three months ended December 31, 2022, from approximately $2,528,000 in the three months ended December 31, 2021.

 

During the nine months ended December 31, 2022, the Company raised approximately $8.9 million in net proceeds under our ATM agreement with H.C. Wainwright & Co., pursuant to sales of our common stock.

 

The unaudited condensed consolidated balance sheet for December 31, 2022, and the unaudited condensed consolidated statements of operations for the three and nine months ended December 31, 2022 and 2021 follow at the end of this release.

 

 

 

 

 2 
 

 

Conference Call

 

The Company will hold a conference call today, Monday, February 13, 2022, at 4:30 p.m. EST to review financial results and recent corporate developments. Following management's formal remarks, there will be a question-and-answer session.

 

Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10175587/f5e2dfab9b. Please note that registered participants will receive their dial in number upon registration.

 

Interested parties without internet access or unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

All callers should ask for the Aethlon Medical, Inc. conference call.

 

A replay of the call will be available approximately one hour after the end of the call through March 13, 2023. The replay can be accessed via Aethlon Medical’s website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 4716809.

 

About Aethlon and the Hemopurifier®

 

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device designed to combat cancer and life-threatening viral infections, as its lead technology. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.

 

The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease.

 

The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

Additional information can be found at www.AethlonMedical.com.

 

 

 

 

 3 
 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to launch its clinical trials in Australia and in the United States and expand its trials in India, the Company’s ability to obtain FDA approval of its new GNA supplier in a timely manner, the Company’s ability to submit to the FDA and have the FDA approve an EUA for the Mpox virus, the Company's ability to successfully treat patients under any Emergency Use pathway, the Company's ability to successfully complete development of its Hemopurifier, the Company’s ability to raise additional funds, and the Company’s ability expand its clinical trials into other areas of cancer, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2022, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303

 

 

 

 

 

 

 

 

 4 
 

 

AETHLON MEDICAL, INC. AND SUBSIDIARY

Consolidated Balance Sheets

 

   December 31,
2022		   March 31,
2022		 
ASSETS          
CURRENT ASSETS          
Cash  $17,499,541   $17,072,419 
Accounts receivable   –    127,965 
Prepaid expenses   672,781    956,623 
TOTAL CURRENT ASSETS   18,172,322    18,157,007 
           
Property and equipment, net   1,212,120    441,238 
Right-of-use lease asset   1,217,458    696,698 
Patents, net   1,788    2,200 
Restricted cash   87,506    87,506 
Deposits   33,305    33,305 
TOTAL ASSETS  $20,724,499   $19,417,954 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
CURRENT LIABILITIES          
Accounts payable   226,791    499,962 
Due to related parties   190,397    155,742 
Deferred revenue   574,245    344,547 
Lease liability, current portion   264,278    126,905 
Other current liabilities   1,180,312    696,893 
TOTAL CURRENT LIABILITIES   2,436,023    1,824,049 
           
Lease liability, less current portion   1,009,277    602,505 
TOTAL LIABILITIES   3,445,300    2,426,554 
           
COMMITMENTS AND CONTINGENCIES          
           
EQUITY          
           
Common stock, par value of $0.001, 60,000,000 and 30,000,000 shares authorized as of December 31, 2022 and March 31, 2022, respectively; 22,969,349 and 15,419,163 issued and outstanding as of December 31, 2022 and March 31, 2022, respectively   22,971    15,421 
Additional-paid in capital   157,148,260    147,446,868 
Accumulated deficit   (139,892,032)   (130,329,181)
TOTAL STOCKHOLDERS' EQUITY BEFORE NONCONTROLLING INTERESTS   17,279,199    17,133,108 
           
Noncontrolling interests   –    (141,708)
           
TOTAL STOCKHOLDERS' EQUITY   17,279,199    16,991,400 
           
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $20,724,499   $19,417,954 

 

 

 

 5 
 

 

AETHLON MEDICAL, INC. AND SUBSIDIARY

Consolidated Statements of Operations

For the three and nine month periods ended December 31, 2022 and 2021

 

   Three Months   Three Months   Nine Months   Nine Months 
   Ended 12/31/22   Ended 12/31/21   Ended 12/31/22   Ended 12/31/21 
                 
Government contract revenue  $–   $17,117   $–   $281,049 
                     
OPERATING COSTS AND EXPENSES                    
Professional fees   729,665    433,404    2,575,496    1,666,333 
Payroll and related   1,048,761    999,500    3,191,402    2,821,850 
General and administrative   1,071,327    1,112,159    3,653,832    2,428,053 
Total operating expenses   2,849,753    2,545,063    9,420,730    6,916,236 
                     
OPERATING LOSS   (2,849,753)   (2,527,946)   (9,420,730)   (6,635,187)
                     
OTHER EXPENSE   –                
Loss on dissolution of subsidiary   –    –    142,121    – 
                     
NET LOSS  $(2,849,753)  $(2,527,946)  $(9,562,851)  $(6,635,187)
                     
Loss attributable to noncontrolling interests   –    (2,214)   –    (4,174)
                     
NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.  $(2,849,753)  $(2,525,732)  $(9,562,851)  $(6,631,013)
                     
Basic and diluted net loss available to common stockholders per share common stockholders per share  $(0.12)  $(0.16)  $(0.48)  $(0.46)
                     
Weighted average number of common shares outstanding   22,946,483    15,397,418    19,741,451    14,543,787 

 

 

 

 

 

 

 6 

 

 

 

 

 

 

 

 

 

 

 

 

 EX-101.SCH 3 aemd-20230213.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 aemd-20230213_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 aemd-20230213_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 13, 2023
Entity File Number 001-37487
Entity Registrant Name AETHLON MEDICAL, INC.
Entity Central Index Key 0000882291
Entity Tax Identification Number 13-3632859
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 11555 Sorrento Valley Road
Entity Address, Address Line Two Suite 203
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 619
Local Phone Number 941-0360
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol AEMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

XML 8 aethlon_8k_htm.xml IDEA: XBRL DOCUMENT 0000882291 2023-02-13 2023-02-13 iso4217:USD shares iso4217:USD shares 0000882291 false 8-K 2023-02-13 AETHLON MEDICAL, INC. NV 001-37487 13-3632859 11555 Sorrento Valley Road Suite 203 San Diego CA 92121 619 941-0360 false false false false Common Stock, $0.001 par value per share AEMD NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $B!358'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !(@4U6>S@WV>T K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>*(YA!Y/FLK'3"H45-G8SMMJ:Q7^P-9*^_9RL31G; ^QHZ>=/ MGT"=CE*'A+L4(B:RF.\F-_@L==RP$U&4 %F?T*E\D5R\SZX__&["+AA[L/_8 M^"K8=_#K+OHO4$L#!!0 ( $B!35:97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M2(%-5JI5PLAL! +A$ !@ !X;"]W;W)KPU'X$4D!P@/>@DA,8T1VK5B\5>8!7;ZZ[7(?GW MG37$IJD9PP7X:UX_.SM^9\U@)]5+MN5:"/!X.>5CWD4&27@^.<@:I7W-('' MVQ_J=\7@83 KEO&QC+Z+4&^'5L\B(5^S/-)/5'P94 8RRHIOLMM?VVY; M),@S+>-#,!#$(MG_LK=#(HX#Z(D ]Q#@%MS[&Q64$Z;9:*#DCBAS-:B9C6*H M133 B<3,BJ\5G!40IT=C^,A9<"1F2:1(2*+[:O.!*91DUU5&W1.NB@M-$"_U.[D3$ MR3R/5_6UC6LX#KUL7;=[UPC/=R.S$-C$6@2LYT^@D>=RC6=DWHR M7)+23J?SA<#'ETK!S$CRS**(0XE+%F+452>@J)'CU,N=K*7&)?U<:%Y0NP[F M,K1J!Q0W],^08[,'$[^4NZ06$)?S64(F@F\D!E>U"8K[_&>XLBP72KZ*)*B? M>%QS[&%H5>>@N.%_1EO(3(/O_"G2T\\*KMAWJ8M9#JU:!\5]OYA##Y:VIU%P M@2Y%S:7J&10W^WL90$X66YE@3:Q!I-^FETZKZV!$59>@N+E_5T)KGD!BXCA/ M#EZJM=@S0HF?J$18*O9?!R07YTKF M1U*FR"N+8*J=WSW+Z:&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT M7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z// MEI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC M**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QK MRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C1 M6/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_ M-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+ M_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5 MUOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO4 M9X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM M\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/ MFD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( $B!35:7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://aethlonmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports aethlon_8k.htm aemd-20230213.xsd aemd-20230213_lab.xml aemd-20230213_pre.xml aethlon_ex9901.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "aethlon_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "aethlon_8k.htm" ] }, "labelLink": { "local": [ "aemd-20230213_lab.xml" ] }, "presentationLink": { "local": [ "aemd-20230213_pre.xml" ] }, "schema": { "local": [ "aemd-20230213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AEMD", "nsuri": "http://aethlonmedical.com/20230213", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "aethlon_8k.htm", "contextRef": "From2023-02-13to2023-02-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://aethlonmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "aethlon_8k.htm", "contextRef": "From2023-02-13to2023-02-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aethlonmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001683168-23-000813-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-23-000813-xbrl.zip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

F.9->@A]6! =$@890-8E+*\P"1(-0+"G:T- M99>4:RT"6\/J8-LRN 8S8_;.P,6!GS/B5;5"Z];W2O_[ M]]/\JZKJ/#\OT],)'E (']&\DBHYFE34*3V-[+^.M3272?F0KQ?._M'3!7IZ M&.CIN6#HOO!4GSPH@8NL@'1E4;@Y=%1Q63,O=QY>'BLOHZ^+^7J9W@*^I#:% M\$E'J^3TI+K1V5Q.BWW8/WK\YGIBG]22>L3S:".$U\F"Z@+WNN[,<2?8BYH-U@WKG>X=8X[.*]: M7K\0%&>>M$>#CF5L.(]L"SXI[O%N]BOSW B.P\@98J'' "N""8U_EX =?.3JMW MGZN.<<16(. (03QF=E99S0F2!0._@%5D48@=3G:XU"X^C%?[@'U@W M-34L;U%-WNI&8'P[@4Z%[O@;!?I46V<-Y81*H:3,1E.)@V8 )#E>4L@5+'#:DR"PWOT4T'9@6+-0,^V=2V]Q,%)LFF;N& MM45*_BL^R)G_C@]Y@B<%\;7CP>))81W%8U,"5G'J0&!+31/66DUN^H,0)XNP M",2*BS>O'E#_$6^PC2&QU5(5I%TU90_XA*HGCT:!\018C+&=UT*(89. M( 5@L'Y3#++[O,-=OW\^GU)^F^@9/7C\S&!VRLWQ6X(P9Y'RB!J&5%*0[?H: M\V4PEHJ 6(SAG'0]87('!8:P3I\:A@R\.@SR(0CH= S!X L>X%(S^UUN,%W^ MK.S+F8-@R;8<)JTCB)5\^LK>?+ZSOA9W;7,+)XD._'G?P!X!L6G@@.;F%D9T M%B9X#Q#4$#T."2;LZ'B%E;:F"UOGK&A5%T#.'&8BZ*$ MH!6(._Z--"W*A>-I$-(&C+RB^O[>:XD2'S(MOYCD4QEEZ<7D9<0F2X8\_HN; M//Y:$G@I)_4VZ\=KG0?#IRUV+V\K$[OC/T(P!R!#K3@OM=!=^=XEOO$L4**]BF6*7 M^DO%KC^UK2=K6RA?]1U7L=Y-Q>H]&,IO_NJG=OVH4;JX;+W)&]A>O:21B+Q5 MRM\"NO.X"+*AY5[VM+6^-K/#BWM'NF>,B$8]W.^1!1'_[4A!$<,!%J !ZR5 MI\/ZU.ABTHV(9#@: &"5Q,-[R1(=]=R^)7J,,=62R.'>UX4B#_U%9&=64?E6AM5I8,C= MT^GQ]DKI'HX*CQ)=LCZ@/)&S+XDF]PNGN&,&EW;2Y#/%/HN;DX:9T MUO^1[^T.#W=..V>=CV=GWG%;<*-2J]Z7,][MQ].KF]-6,Y_A'^UO7RN5^M$7 M\_S<*%>JK:N\L([ZM][=Z*12_?G#%:UAN=>Z' VXN]/:%9W/'P_-WH7N'K?O M;_KWE\>V]^5'_NS!^5;NIX^W1[IK] ;US_I%\T?ZJ*KU9V^.!' MV]8ML_9=.:DURC_=]JAUQW+'/S]J2MTY:W35+WJ5JH/;A_)ENW_\\8LZO#FJ MYR[O&!L>:Z=7/^C)]\KGR_KIC[.;]/?.WFZY>63TYSYS1=N=GMGE[> M=L*9PK__!U!+ P04 " !(@4U6=<2B7_@@ !^$P$ $@ &%E=&AL;VY? M97@Y.3 Q+FAT;>T]:W/:R);?J>(_]&8GR*\_GO7._V3]P9^=UB]O1JX3?&!J81:P@37E M/NOR&W;E3G5'$1\HK,\]:_0&;H1;+Z/[IKHWMIP/K/#FT\>S3ZWO$VMH!:Q> MSZL?3\[@J9?;K__9&?JST_5+=@7EE,6+P:4(P.=>=Y!<)3?2IY8]_W#7E@#R MC^V+7UG_JOG+&VNJC_G_%0IJ_J_9^ UK= :_O'D3K3KAUG@"T)6U67#*;BPS MF "HFI:OEFY'3;&L-'!G<"[A'($?XVH?F0G]7@ MP<1V'7;!3>>VV9<'73]6:NIP>;OW:4]AG/O1@EW.FEA16 M+!1++)=C*WA16-LQ\NQ=5_=-_>\/K-&Z.'^O9#,ZFTK$!1/NZ3,>!I;!#'%\6/NX*V6,^)&8+FA#W?Z7/=Q@X%KZO-LQN- @ ">-HI(Q3Q)J9'K M,0L?2"3]6Y*4.R9AS?AWUW?Q69&PY)+",*S MF:^.A<#W ]07DG$&4]<#MM7A4QG^-G1-"P'Z@\,3 M; NV+>0D0 #%2C>6;;,)MV=H+UQO2F(/1AIL/\KV* Q"X&@^&L$^C+FXR<=O M$$E)J4_N+I_-) F-&R4+!M@(4""2 (PLSP\VXM7!3Q&<9?2FF;W_X NN!OL) M0'3261*%38'34V4T0WT*6S+GY#512Q.79L;H:U[]CP7 ,@< M\6EZX1BUAP%JTIO#\T8!^1*23" RZ%*#V@N'2\IN:+FSR=RW#*%+X4]CPJ<6 M4&^.NT,O +P%;^SI9HC$!H8#"L(S?.1H / /^-0#':L XS& &H5 1^S@ZCUO MK(/0 '*B-4DG+U;(9F")A@UN2*#G60)10PYW,N0L0_>XX,@9JG\]8<<"UI^# M0_L],861HBEL)LVJJ0;ETW!'<2[X3JXF_Y"9K& LQST@,&, M_<4-P5^Z,[;<,7KU-\#[7SV M._ \! =PKRD]BJL$N7K]-K &4M$@#P#4CY*D.H(LT :&(69G=&U!S( \D<)- M*GW OVF1#WE53/2F^3[6N2N+0]EUT<<@:(AOX6W432$R_ M]YYHSIP0@P$2 0M"P6NIH4#!!+EPAHHA &OL"/R+.(?,T6^@Z8%]@*.1+5#> M$/UK450"P$CLX-G"%76!NJADD%LN=0\,5C8#(D+:D:QY)+<6G1 41A90 M HH+T,J]W]OG#" T04H,TF/H% 8A2HZT8V0[$QR&D.CF-0HSZ0Z09W2C03 " M],@ *91T<4%49^CR>=R&)9'E8-O+OH&(N_J-JWZNZ?Y>%,84Q$>M@NYV@HF? MU'0_>S[RHR^U$")=""[: W]BS81'90U#$G+T%E>4O? K$A*!S@_JZHE^S64H MR$TAV>CL0H0G#8;@=+4"&SIZPA:.0"_^$3,K:WA.N@R+<8L$S M^"C F/ IP*WB&/P:$W1DA&D#/0_ND1'B7P)>W!ZK:XR,%E%[ADZS3$$D_7;T M']'=!KV*E'58JF3!\J1;E)NA'&Z[_+<\^XZ:!QW[S@/TO MP-] 9T,(<^L[^ #$+5*6%10!Q)O4>C?@RA)&@5A )N&:$D M7$!2'( ^_AWP[./R"_,KY5$H:7&E+65%9C:6F ?$:X0+S) $$-MD,PFM ;X5 M^ S?4%!N0.()-AF@P2T)YI?.:6PN"5"IP]-,Q1X [3IC%Y4AJ:.<6E_X^VV0 M*YVT!#"T%3EVB,EV\RMB#O0F^/QZ-D,*%%VM+ZX_LP)28!359%A$CR \IQJ 4C_@O%2_Y7+@9!RV_P AFO,3^'ZOT,4 M$EB6Y7*R.O#QO/W[W2&7+I7>+O ].-]TA?9V M2TXZ@OJ4RY0W741OVKRII/H+OQFV]-+*T_W4#DN M@WPRN,+_(,[A)]!N QF'($_?!*9H+*'D^/>9#.C8(FL'QL^. DC\)IF^ MB-R+: T1%G"Z[L)UOO'YS/W.WDTOW>_O<76 D-0F>:$W^ISB-3V F,<&DF%Y&*0'N"_,A5B4@L%'LB$\@,%: M$*9A<$BAL.MLRL.D6$]OT@<14>.T"8DV^7* 0-@SY@K(202$./X(,Q1C<"\6 M-DMDX)K]SW%=2L3'9."$GX^9.PP47 CJ=/"!N- 6ML[QX]C61DE5A[V[;/2; M&-4A:-\<]\;!B$"Z21TW8: CQP+L,V6ULAEZ'(0>7.36<&/DTT D.<4DWW1F M1XGFV)+31O"9E!^ZP42!OO$:$37%$.-G;AC0KXZ.) MW<%5DBE,8DU@8$KWQ6RI@R<_A_ =KX[3U6C[.> RYN)K2Y>92<0G/I4BI62& M7N27(NQG,P?"G%3ZB2N7["I1#L.-+U MGF(A-261R%N0.5UI_77VDZJ5UQX25=28K0\QS!/H3%8DI379$(,#-1)%!C(+ M@:@/+VIE\-AJ:>VIB=L )_RQ[$PB9O4M9ML/I:($*DEN I4T=)5*V!C^X+A MA9B"'4=N6\PP)(,@8^CPV6BE%KP'F*)UDSR(M9+061+Z0V0T(6M+>*4BYFTR MFF"[;&9=(U =:*%??E(K5?D,\&%L+ #$7$4%]^6K*X*$\*L?N :$/3KVMJ#Z M@UL$]T:W1X %+B8JQ1J8+=)-(HW"-NH/ JE6B$""15QC:=T4DS$B6F&=';>H MP745D]D6B9SW #]?A<\QC$FI!V1&H^4L@?J MU@EY1-6DQ<]FMG1:4?Y3K E?@\^EJ&J5K.C]'K#=I5CV"A=NC2+J([(&0B[A MLHM3KFJ1L)L< C3T;R((%L(-JV ?PP9P?1%#B*H#KH+H$VE^JAD86.G%(K8% M@5/@.@MYB%<@,\"Z[2],I]QPC FQ6R!+G\\"L6.UG.A=NZ%DLR_*!Z+CZ>^0 M"O,R$01(:HN1?!06(C\ M;5#)!>DY=JQ_T,3%*,/K8YPND@,1[4':_'4\NT+AKS?H17Z[/^$\.#216F8+ M0N1$=\:" >3616$GUI3 .UB9&P*;4>TCFW% \0!9%NXR<>.JFZ[4RK$QV5%F M0#(H0E];JERLK2V5S=PA?X=%&MFO@-MS,#=P%Z*2*L33+9_X>!EOM7P]#H8 MCYH2[JF^"U M\+AS"<1VBLV#Z)P<&.I1TX6.'IK4% 6:Q43.I]\6L>R2V%-LF21*-B.H$J5( M[UR.ZH2BY(H(C/M'5J)67&\'=J#KD.FSF1&XI^Y-5)''YKPH6066 X7U0'J& MC^N*=9=6O*7453R6NO9?ZBH>2UU/B^" S# JZA2E:B+@9P6!Z>;<(N%_#6 MJ:>0A3,W@E>X&H_G!RPC[*\02#^:[YDL\5,V4":JX5GX%7J]NF$ \S%L+@;' M;&A38@>(D(OIAZ=(),8PIX+B!D3[L&_@+QM7@W:S?=D -7'>;G18NXN]KIT. M^WS5:KW_P'[^[_JIFJMI6JY6JN1J54U]2I#:W4'KJML8M'M=@$T"& &EJ<5< M2:WFRII6W#=0#6SV!IIPSP<'W U1/_K?8JE;;73-9J@5?2&,=/-A,[P,X#%_ M8NOS.'I'NQ#KW6O=LHF]5VI7V(0VP2!-IP,)2X&!7 /"#3<<3]@%-?A%9S%% M%D@^DLZ"<2E,'/M(]57,QWVT-WSH6WALT4-Q0LFBQ!.PIXG3P$+58A.(HM$Q6_Q?' =/N'JT=CA2G M<.Y]?E=D#9,XP)Q[HF$)G5S1\)Q<$Q; ,Q'B&);(5V'=;_W [^H91C()LHG% MIUX2/)R)O;$ 2=R+G\=FE4D(2(C:G90U6E&OK@D?.&2!X^QHU+NT_0@E]?JN M'KI&:>Q0-T#&V$VY&EHB2T*PTSV;.,**+ MM.ZY8$\\D6@0:\19($15?"P8OKZVS!![MRA/%Q^5@*LEMDF !$O?3%QJY^<6 M2@(+': ..('44 [\CZ?2'5"E("1.0!U\<#M$%AX9!NPXEU(Y%^2C)\JE XB2 MB3U$:2IF"VHD''+NH)6^<+)UVQL PG_1 "6D6W+"83&":*2$ MR(U:]X'<;!.%(PZ(A02NI=[Q]GDK*7O+99X5/MBJ*"A&0,)1O<E89%V!4.J5._L%2ZX2_ZR=,Q? M[C]_63KF+_?;[2I.4N4ZKOL-%7,_KO(EC^$(=!"*]F^7/1BK#\&0:RCBD_RV;$3QSA ML'R9//Z]_"'&]ALOHWAD^=$024_7 (I=>WLN/T>7RYI:MNYE,P"N]-D)+[!" M@,W\V^F<9WW$UBV,@/Z''U*K/!6)06U@ R/6C+>01WI"!AT-CK+3(B.'(T?B M$PNVG%P@Y^C()'9$!S-R+V\#7O0V;K]"'-<4 1-E3*5S\2\_:AR1S28R0A)Q MC6 ^W??#Z4Q\3ER)6W#0N8UW@(TIKA=%3\(/'Z)?;+@>#DJ!* +0X'H^.L)R MA?CD,5U-O"KP0N>RHV,U2ISUM(&V KRE)@'80730 "<'Z$"!"<6R&XX.QX-# M!&4V#0V)>D3H^\!/W$S'*I<>'6>%$@"X0^I 0C]9>*8B!L:E<)#'K]T&!92V MF(-",XM ;P$'3''$BW?G^L"!@(;(?:;'4!0M\N.)YV*-G;6^-N*0ZP*/)9%' MO05_0!NB Z;!("2WYW)T6'RN1/168 JC->7>&.@T9U]].@) M[Q:)!9)]D9Y#)T"<-;,A0L8M;5$,&%V#_@OC]LTA9O6I)0E@F^B8>+WF>98( M%D9+\F-0JMB "Q<:@Z82;=$K8A;M0 D972PI\#^B M*49^XEQ7PI[B?;%-A3NG%EF"Y 0/)+V<6 =8$O#Y20#_ ]C';.PM6!+F-M+/ MD7.!/>?"N_!GX!N*X0S$1R)'((?>B00#?#(7C>A3W02" ]0<'!9=F(EAHLEP M. ?==K/<'F6ZHHV-24,,OWOB0RO BI")'/>-D\2:(0Z, AZ1<_<"<2QD$8%2 M176$F;5XE-.U:./QQ''#*:91# JOVX_LFD4NW^.NNYC/UT12&<$'ZKCU[%/;N<86 M66\#;OJA#PJ@ZX+><>0G^49>?D#R%#KQ: RT_!Z0=38 M%2XF]FFT!E\ZO2Z[:)VWFXT.6,QN$QRJ+I#@ZUF_?=YN7/WY?- MG>4]D_W/ M?>Q_]B.@4J]M]J8&=IT@CV/IM^H(@>XW$:>#)&W6 Z1W;N1 =B3R*%T'8XVX<->E.7 ,@KG64>N/ANV*IILA_[Q.<=:_M@V;J]UN#_IVTV(+V MW9XE#.+.5+_#!.WGL2]C@S_$5'^(-N6US6\8_O#UZJK5';!EYKD5@[NB:V?< MW+5@FJ#9MZQ+HU6IO%WH3(0B\EZ;NC_9XO05W][.^9$]?+N)]7[:LJBZQ9-4 MJXI6KRME[&[=?./&Q]SJ,S_U!@K5HJ*I]0=OX$E$=#,;-,3(!E]VD&,'Z?ZE MQ03>2XWPJL6J4J^4TR6]VXFWY$]LHNBEQV>ZM3C$NX-CH-&ASVM?Z#6 M%!5XI[3NES^;F@&(RCCTI9H.39-BURA=T#R+<9::',^&R_>68)&+RL *'N;? M.[$J<0M<[YS/6MX*##DU))*176(L=7$YT\VO:?/YHNYLOK M?%HD1A7AR^:<^,9E'D ONH^9;CBT^4XYJ7NN$FGV@E(M:IAOVVDC#^?:E.-! MK2L:^$;ULO8H>'A4/9KB2"A=T*2D6-9I-\[:G?:@W>J+XOV@U_R?+[W.>>NJ M_R_6^L_7]N#/-*(O7= <1>C@L/X N[NH$B:D)HV(21M4KROURCUSR,\=# O*G8L1UM%9^)C'I!*=7OF>+>(SCE MLE+5GI)^/R9NYRN3B/>-'QR,7-3N6?O<'S@E35/*6DH*)/>C7(<2NW;T0I_X M=9T,3\U8KK-WQ5D!2E93DT-408_7UW,#J1*\.ROI/3I&%1$RHJUUV"5U5<$7 M/934W1H67V+:"NL0M?JS%]5W4#T/J:\_H6==5+1212FL]R<\F]91:D5-*6AK MZ:UC\)D^:)[$;ELX@!UD)Z=N%)Y[&(,U V_CE(PM5OX0U2*^3*H./L2:^_5Z M#$.AJ)2?OZ!QJR<3,[2P!CNP[^UF8X.Y.$32E11-*RNE];KUJV%>,,;@ZLQ&[^*B/;@ MU'4+IJ][J#=_;75;1[SLL_HP:1XR^F" MYG$=]V.M[LCV+Y\ /]+++S]9"JKPJ/CB[5\*%AK8M6Z'XJ6BA7RAH"I,O*0R M?N%Q:?&G/]$]'$<4!A/7L_[!M\UM?I\VW;@Z_0BG&HO7LMOS4P:?U"MUI:35 MZ6*UC(>R%+528I;OAUQ,:';#@&8=T\3L!SYJ[XD5V$@U-44PQ&/QGM"D(RF_ MF V6HR-1---\9@6ZO7^<5155 _ KJ>F@5[4J!$D5I59)=POVG9F8AF&$TU"4 M-4T^L@PK6-W0(05N[]127:G5BTJA]-"<_/L#WW]!*15!43_XH-_[Y\@H+B=@ M=LFU;&H-8V>MS[VK%NOVNAA]7?4Z'8C Q-MW6OTG."A758I5P/UZ2^BSZ2G0 MG*62HA:>4TVEV/M+%S3/W[I-NJWK.C0KUZ5W=XFW?W'_L$\7;#DG_VHRFN]4 M356JZVK@"8W"42T9PL>9PO>?*9QX*9,[8KT9%V_+])\/O,_1>S/GSXM8+913%X MP5#N'(D<[+#N%FDMM7A24D]>R8SNI2WO5EAZ45L^4GG/,]COF_-)(.&6ZP_[ M]B<::JT5-HY4_M6%ASGTJCPJ!NE&L'J0=F6A_0R*7KW\]GI.VL9<;X$>R[+J MVMF0 P'^L%%?K*F;#K4]SWCQ%&>4C] <"C1//WBF=]FZ:N#A!C!E?7G1C_Z37QI3['-BW*F,KI1/O'34&K*=5* M:EKJZ_C&F_L.6=X?."5%I6:*U+PLH:C4BJI2*S_E&.H?ZE2'X),[W-,%6^OF MU'*LZ,WE.V0ETMMGHQ2JJE(JOMZA "J$O45%+;_>7JN24BF7E-J#3R<&WQI744% MM?VC)%4OD#Y\?DD7-,^9Q>VXOL]W5O$H0>!9PW# M %^QAV]M??:G=.I7_3N?YCV1]M[A":UT#R=[7WSZ0\:2(3OJ()'X%!*)Z0!@^XH-I_B M35F)]U<]EP*Y1V+L[EG#12RK*5KMX6[\;@G"0T"&6E9*]:JBJ0^W*B\(&76E MJJF*]@,Q[@M"AJ:4M9)2O;M7^3B*^KA@.J9O5TY9;T8S?3^PCNX'QV'G/7.__R$OWP97'0^_3]02P$"% ,4 M" !(@4U6D'#4S54# #+# $0 @ $ 865M9"TR,#(S M,#(Q,RYX&UL4$L! A0#% @ 2(%- M5JPU4IY